JAK3 and glioblastoma: Coinciding with the ability of tofacitinib to block JAK3 phosphorylation (Fig. 1K; Fig. S1E), this JAK3 inhibitor muted the ability of CTRP8 to enhance GBM motility (Fig. 2I,J).